You searched for "Blindness"
Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO
This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...
Foveal displacement after macular hole surgery
Previous studies show that internal limiting membrane (ILM) peeling during macular hole surgery is associated with retinal shrinkage (microtubule depolymerization of the axons of the inner retina) and nasal shift of the fovea. A temporal inverted ILM flap technique was...
Hess vs. Harms vs. PCT measurements
This study aimed to compare the results of the different tests in 36 strabismus patients and 18 healthy controls aged 6-81 years. Tests included alternate prism cover test, Hess screen and Harms screen. Because of glasses restrictions with the Harms...
Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy
This is a retrospective observational study of 82 patients, between 2014 to 2016 from Switzerland of treatment-naive patients with nARMD, treated with AF, with specific T&E protocol without a loading phase and predefined exit criteria and patients were observed three...
Outcomes of chemo versus no therapy for optic pathway glioma in NF1
The aim of this study was to evaluate the visual outcomes of a cohort of children with optic pathway gliomas and neurofibromatosis type 1 (NF1), with comparison of children treated with chemotherapy or not. This was a retrospective study of...
Depth and width of corneal wounds post corneal foreign body removal
This was a prospective study of 63 eyes of 63 patients undergoing corneal foreign body (FB) removal with a 27G needle at the slit-lamp; 96.8% of the patients were men with mean age 35.8 ±11.0 years. Regarding location of FBs,...
Acetazolamide and CMO
The authors set out to analyse the effect of acetazolamide therapy on inflammatory cystoid macular oedema (CMO) as defined by change in central macular subfield thickness (CST), as well as its effect on visual acuity. A retrospective chart review was...
Diclofenac versus Bromfenac after cataract surgery
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used after cataract surgery to reduce inflammation and cystoid macular oedema (CMO). Diclofenac 0.1% is used three to five times daily for 28 days and Bromfenac 0.09% twice daily for 14 days postoperatively. The...
Prediction of visual outcome in IIH
In this prospective study, visual outcome of 40 patients with idiopathic intracranial hypertension (IIH) was compared with clinical and neuro-ophthalmic parameters. The purpose of this was to determine any correlation to try and predict visual outcome for IIH patients. Parameters...
Radiation maculopathy
This is a retrospective non-randomised study of 13 consecutive eyes of 13 patients affected by radiation maculopathy secondary to eye irradiation for primary uveal melanoma (Iodine-125 brachytherapy). All patients were treated with a single intravitreal 0.7mg dexamethasone implant and full...
Brolucizumab in age-related macular degeneration, HAWK Study
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
